Between February 1993 and September 1995 , 739 patients with metastatic breast cancer were entered on an Intergroup trial ( E1193 ) comparing doxorubicin ( 60 mg/m ( 2 ) ) , paclitaxel ( 175 mg/m ( 2 ) / 24 h ) , and the combination of doxorubicin and paclitaxel ( AT , 50 mg/m ( 2 ) and 150 mg/m ( 2 ) / 24 h , plus granulocyte colony-stimulating factor 5 mg/kg ) as first-line therapy .
